2 3 4 5 6 All forms of PAH share equivalent obstructive - - PDF document

▶
2 3 4 5 6 all forms of pah share equivalent obstructive
SMART_READER_LITE
LIVE PREVIEW

2 3 4 5 6 All forms of PAH share equivalent obstructive - - PDF document

Mar 07, 2023 14 likes •639 views

2 3 4 5 6 All forms of PAH share equivalent obstructive pathological changes of the pulmonary microcirculation This suggests that there are shared pathobiological processes among the diseases associated with PAH 7 7 Right

slide-1
SLIDE 1
slide-2
SLIDE 2

2

slide-3
SLIDE 3

3

slide-4
SLIDE 4

4

slide-5
SLIDE 5

5

slide-6
SLIDE 6

6

slide-7
SLIDE 7

7 7 ¡

  • All forms of PAH share equivalent obstructive pathological changes of the

pulmonary microcirculation

  • This suggests that there are shared pathobiological processes among the

diseases associated with PAH

slide-8
SLIDE 8

8 8 ¡

  • Right heart catheterization (RHC) is required for the diagnosis of PAH to

assess the severity of hemodynamic impairment

  • Left heart catheterization is required in circumstances in which a reliable

pulmonary capillary wedge pressure cannot be measured

  • new 2008 guidelines removed the exercise induced elevation in PAP from

definition – all have some degree in PAP rise due to increase in CO with exercise – how much is normal vs. abnormal is unknown – and all pts with mild PH will raise their pressure with exercise

slide-9
SLIDE 9
slide-10
SLIDE 10

10 10 ¡

  • The Dana Point classification scheme for PH has 5 clinical groups:
  • 1. PAH , 1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary

capillary hemangiomatosis (PCH).

  • 2. PH owing to left heart disease,
  • 3. PH owing to lung diseases and or hypoxia,
  • 4. PH Chronic thromboembolic pulmonary hypertension (CTEPH),
  • 5. PH with unclear multifactorial mechanisms
  • Each PH group in the Dana Point classification scheme is also divided into

subtypes with specific characteristics Clinical Classification

slide-11
SLIDE 11

11

slide-12
SLIDE 12

12 12 ¡

  • Group 2 of the Dana Point classification scheme is PH owing to left heart

disease

  • This may include subcategory 2.1 , 2.2 and 2.3
slide-13
SLIDE 13

13 13 ¡

  • Group 3 of the Dana Point classification scheme is PH owing to lung

diseases and/or hypoxia

  • Possible lung diseases associated with this class include: chronic
  • bstructive pulmonary disease, interstitial lung disease, other pulmonary

diseases with mixed restrictive and obstructive pattern, sleep disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude and developmental abnormalities

slide-14
SLIDE 14

14 14 ¡

  • Group 4 includes Chronic thromboembolic PH or CTEPH
  • Group 5 includes :

5.1 Hematologic disorders : myeloproliferative disorders, splenectomy 5.2 Systemic disorders : sarcoidosis, pulmonary Langerhans cell histocytosis 5.3 Metabolic disorders : glycogen storage disease, Gaucher disease, thyroid disorders 5.4 Others : tumoral obstruction fibrosing mediastinitis, chronic renal failure on dialysis

slide-15
SLIDE 15

15

slide-16
SLIDE 16

16 16 ¡ This table shows the prevalence of common symptoms in PAH. The two columns are for the prevalence of symptoms at the time of diagnosis and the prevalence of symptoms during the entire course of disease. There have also been some reports that sleep apnea is associated with PAH, particularly in the presence of bilateral leg edema. At the present time, however, there is no consensus that sleep apnea should be listed as a key symptom of PAH.

slide-17
SLIDE 17

17 17 ¡

  • PAH tends to be diagnosed late in the disease – generally due to

patients being asymptomatic until late in disease, under-recognition, lack of screening of those at risk, and the non-specific nature of symptoms.

  • Early in the disease process, patients are generally asymptomatic,
  • ne of the reasons for late diagnosis.
  • Dyspnea on exertion is the most common presenting symptom,

sometimes accompanied by fatigue, dizziness, palpitations. Later, other non-specific symptoms may include chest pain (which may be indistinguishable from coronary artery disease), recurrent syncope, coughing.

  • The non specific nature of symptoms can lead to confusion with
  • ther conditions such as:

Deconditioning Psychological problems (depression, anxiety) Biventricular heart failure Coronary artery disease Asthma, chronic obstructive airway disease

  • Late in the disease there are characteristic symptoms and signs of

right heart failure including edema and ascites.

  • Diagnosis requires confirmation of PAH with RHC and evaluation of

etiology.

slide-18
SLIDE 18

18 18 ¡ This slide lists the most common diseases associated with PAH. Patients with collagen vascular diseases, most significantly scleroderma (SSc), but also lupus and mixed connective tissue disease, are at higher risk for PAH. Congenital systemic to pulmonary shunts are also associated with PAH. Such patient types include those with ASD, VSD or PDA, as well as those with Eisenmenger’s syndrome. Portal hypertension and HIV infection are also commonly associated with PAH.

slide-19
SLIDE 19

19

slide-20
SLIDE 20

20 20 ¡ As might be expected, New York Heart Association functional class at diagnosis is highly predictive of mortality. Most patients with PAH are symptomatic at diagnosis. The level of symptomatic deterioration is highly correlated with the patient’s underlying hemodynamic function. Literature reports of survival of patients with scleroderma with associated PAH vary from 45-55% at one year to approximately 30%-50% at two years.

slide-21
SLIDE 21

Reference: Humbert M et al. Survival in patients with idiopathic, familial, and anorexigen- associated pulmonary arterial hypertension in the modern era. Circulation 2010;122:156-163.

slide-22
SLIDE 22
slide-23
SLIDE 23

23 23

Let us turn our attention, for now, to some general information about echocardiography, the anatomy of the right ventricle, and have a brief look at echocardiography technologies/methodologies.

slide-24
SLIDE 24

24

slide-25
SLIDE 25

25 25

slide-26
SLIDE 26

26 26

slide-27
SLIDE 27

27 27

slide-28
SLIDE 28

28 28

slide-29
SLIDE 29

29

slide-30
SLIDE 30

30

slide-31
SLIDE 31

31 31

slide-32
SLIDE 32

32

slide-33
SLIDE 33

33

slide-34
SLIDE 34

34 34

slide-35
SLIDE 35

35

slide-36
SLIDE 36

36 In patients with pulmonary hypertension, the flow profile within the pulmonary artery will also be abnormal, with a short “acceleration time” (AT). The mean pulmonary artery pressure (in mmHg) can be estimated from the pulmonary acceleration time (in ms) using the regression formula described above.

slide-37
SLIDE 37

37 37

slide-38
SLIDE 38

38 38

slide-39
SLIDE 39

39 39

slide-40
SLIDE 40

40 40

slide-41
SLIDE 41

41 41

slide-42
SLIDE 42

42

slide-43
SLIDE 43

Figure shows effect of contrast enhancement of continuous wave (CW) signal

  • f tricuspid regurgitation (TR). A. Before contrast enhancement, TR signal was

not detected. B. With the injection of 10% air – 90% saline mixture or C. 10% air – 10% blood – 80% saline mixture, complete CW signal of TR could be

  • bserved. But the air-blood-saline mixture exhibited a higher peak velocity

compare with air-saline mixture. 43

slide-44
SLIDE 44

44

slide-45
SLIDE 45

45 45

slide-46
SLIDE 46

46

slide-47
SLIDE 47

47

slide-48
SLIDE 48

48

slide-49
SLIDE 49

49 49

slide-50
SLIDE 50

50 50

slide-51
SLIDE 51

51 51

slide-52
SLIDE 52

52

slide-53
SLIDE 53

53 53

slide-54
SLIDE 54
slide-55
SLIDE 55

55

slide-56
SLIDE 56

56

slide-57
SLIDE 57
slide-58
SLIDE 58

58 58

slide-59
SLIDE 59
slide-60
SLIDE 60

60 60

slide-61
SLIDE 61

61

slide-62
SLIDE 62

62 62